LiquidCell Dx

LiquidCell Dx is a precision diagnostics company focused on developing a blood-based platform for tumor microenvironment (TME) profiling. Founded in 2022 by experts from Stanford and Mayo Clinic, the company leverages advanced liquid biopsy technology and computational biology to analyze cell-free DNA (cfDNA). Their platform aims to provide insights into immune cells, stromal context, and the multicellular environment of tumors, which are critical for predicting drug response and personalizing cancer treatment. LiquidCell Dx is headquartered in San Carlos, California, and is led by CEO Mirna Jarosz. The company's mission is to transform how disease is detected and monitored by bringing cutting-edge liquid biopsy research into clinical practice.